

VHL14 Circular RNA for Cancer Vaccine Research

Catalog Number:CVAC-ORNA-0483

DESCRIPTION	
Product Name	VHL14 Circular RNA for Cancer Vaccine Research
Gene Name	VHL14
Source	In vitro transcribed mRNA was further circularized to make this product as a circular RNA.
Alternative names	VHL14 Peptide
SPECIFICATIONS	
Cap	
5'-UTR	5' -untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence
ORF	VHL14
3'-UTR	3' UTR comprising two sequence elements derived from the aminoterminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA
Poly(A) Tail	
Modifications	N1-methyl-pseudouridine
Neutral Lipid	1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)
Cholesterol	Cholesterol
Lonizable Lipid	1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000-DMG)
PEG-lipid	Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate)(SM-102)
Storage	-80 °C
Buffer	PBS, pH7.5
Cryoprotectant	Trehalose
BACKGROUND	
Gene Accession	
Gene Alias	VHL14 Peptide
Background	Description: A peptide vaccine derived from the von Hippel-Lindau (VHL) tumor suppressor protein, a general transcription factor. VHL14 peptide is a point mutation variant of the VHL protein; the mutation is in amino acid position 166. It might be used to elicit or boost cellular immunity to cancers that expressing the von Hippel-Lindau mutation. (NCI04) (NCIT_C2741).